Retrospective Analyses of TrakStar Database
Launched by NEURONETICS · Mar 31, 2025
Trial Information
Current as of June 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different patient characteristics and treatment details affect the results of a specific therapy called NeuroStar TMS, which is used to help people with depression, obsessive-compulsive disorder (OCD), and anxiety-related depression. By examining real-world data from past patients, researchers hope to better understand what works best for different individuals. The study is currently recruiting participants aged between 18 and 43,829, and anyone can join, regardless of gender, as long as their treatment information is complete.
To be eligible for this trial, participants need to be male or female and have a valid age recorded in the database. They also need to have received treatment on or after November 1, 2008. Unfortunately, if there is missing information about a person’s treatment, they won’t be able to participate. If you join this study, you can expect to help researchers gather important insights that could improve future treatments for mental health conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female reported in database and not an invalid entry
- • Age reported and not an invalid entry
- • Treatment date of November 01, 2008 or later.
- Exclusion Criteria:
- • • Incomplete information on treatment parameters
About Neuronetics
Neuronetics, a leading medical technology company, specializes in developing non-invasive solutions for neuropsychiatric disorders. With a focus on innovative therapies, Neuronetics is dedicated to advancing the field of neuromodulation through its flagship product, the NeuroStar® Advanced Therapy System, which utilizes Transcranial Magnetic Stimulation (TMS) to treat major depressive disorder. Committed to improving patient outcomes and enhancing the quality of life for individuals suffering from mental health conditions, Neuronetics actively engages in clinical trials to evaluate the efficacy and safety of its therapies, fostering a robust pipeline of research that underpins its mission to transform mental health treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malvern, Pennsylvania, United States
Patients applied
Trial Officials
Eleanor Cole, PhD
Study Director
Neuronetics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported